Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

被引：11
|
作者：
Tettero, Jesse M. [1 ,2 ]
Ngai, Lok Lam [1 ,2 ]
Bachas, Costa [1 ,2 ]
Breems, Dimitri A. [3 ]
Fischer, Thomas [4 ]
Gjertsen, Bjorn T. [5 ]
Gradowska, Patrycja [6 ]
Griskevicius, Laimonas [7 ,8 ]
Janssen, Jeroen J. W. M. [1 ,2 ]
Juliusson, Gunnar [9 ]
Maertens, Johan [10 ]
Manz, Markus G. [11 ]
Pabst, Thomas [12 ,13 ,14 ]
Passweg, Jakob [12 ,14 ]
Porkka, Kimmo [15 ]
Valk, Peter J. M. [16 ,17 ]
Loewenberg, Bob [16 ,17 ]
Ossenkoppele, Gert J. [1 ,2 ]
Cloos, Jacqueline [1 ,2 ]
机构：
[1] Univ Amsterdam, Locat VUmc, Med Ctr, Amsterdam, Netherlands
[2] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[3] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
[4] Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany
[5] Haukeland Hosp, Bergen, Norway
[6] Erasmus MC Canc Inst, Data Ctr, Dutch Belgian Hemato Oncol Cooperat Grp, Rotterdam, Netherlands
[7] Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania
[8] Vilnius Univ, Vilnius, Lithuania
[9] Skanes Univ Hosp, Lund, Sweden
[10] Univ Hosp Gasthuisberg, Leuven, Belgium
[11] Univ Hosp, Zurich, Switzerland
[12] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[13] Inselspital Bern, Dept Med Oncol, Bern, Switzerland
[14] Univ Hosp, Basel, Switzerland
[15] Helsinki Univ Hosp, Canc Ctr, Helsinki, Finland
[16] Erasmus Univ, Med Ctr MC, Rotterdam, Netherlands
[17] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 10期
关键词：
ADULTS; AML; YOUNGER;
D O I：
10.3324/haematol.2022.282639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2794 / 2798
页数：5
相关论文
共 50 条
  • [31] High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia
    Oya, Shuki
    Ozawa, Hidetoshi
    Morishige, Satoshi
    Maehiro, Yoshimi
    Umeda, Masahiro
    Takaki, Yusuke
    Fukuyama, Toshinobu
    Yamasaki, Yoshitaka
    Nakamura, Takayuki
    Yamaguchi, Maki
    Aoyama, Kazutoshi
    Mouri, Fumihiko
    Nagafuji, Koji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 297 - 304
  • [32] WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates
    Cho, Byung-Sik
    Min, Gi-June
    Park, Sung-Su
    Shin, Seung-Hwan
    Yahng, Seung-Ah
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Kim, Myungsin
    Kim, Younggu
    Kim, Hee-Je
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (10) : 1925 - 1932
  • [33] Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis
    Li, Zhichao
    Liu, Yinmei
    Wang, Qing
    Chen, Linjun
    Ma, Liyuan
    Hao, Siguo
    ACTA HAEMATOLOGICA, 2019, 141 (03) : 164 - 175
  • [34] Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Liu, Jing
    Zhao, Xiao-Su
    Liu, Yan-Rong
    Xu, Lan-Ping
    Zhang, Xiao-Hui
    Chen, Huan
    Chen, Yu-Hong
    Wang, Feng-Rong
    Han, Wei
    Sun, Yu-Qian
    Yan, Chen-Hua
    Tang, Fei-Fei
    Mo, Xiao-Dong
    Liu, Kai-Yan
    Fan, Qiao-Zhen
    Huang, Xiao-Jun
    Chang, Ying-Jun
    CHINESE MEDICAL JOURNAL, 2018, 131 (23) : 2808 - 2816
  • [35] Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission
    Yano, Shingo
    Yokoyama, Hiroki
    Yanada, Masamitsu
    Mori, Jinichi
    Aoki, Jun
    Ohashi, Kazuteru
    Kanomori, Heiwa
    Ozawa, Yuichiro
    Sawa, Masashi
    Nakamae, Hiroshisa
    Eto, Tetsuya
    Ohta, Shuichi
    Tanaka, Junji
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Takami, Akiyoshi
    BONE MARROW TRANSPLANTATION, 2019, 54 (12) : 2004 - 2012
  • [36] Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia
    Al Hamed, Rama
    Labopin, Myriam
    Daguindau, Etienne
    Niittyvuopio, Riitta
    Huynh, Anne
    Socie, Gerard
    Srour, Micha
    Bourhis, Jean Henri
    Kroeger, Nicolaus
    Tholouli, Eleni
    Choi, Goda
    Poire, Xavier
    Martin, Hans
    Rubio, Marie-Therese
    Jindra, Pavel
    Blaise, Didier
    Beelen, Dietrich
    Labussiere-Wallet, Helene
    Nagler, Arnon
    Bazarbachi, Ali
    Mohty, Mohamad
    CANCER MEDICINE, 2022, 11 (04): : 1068 - 1080
  • [37] Post-Transplantation Day+100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission
    Klyuchnikov, Evgeny
    Badbaran, Anita
    Massoud, Radwan
    Fritzsche-Friedland, Ulrike
    Freiberger, Petra
    Ayuk, Francis
    Wolschke, Christine
    Bacher, Ulrike
    Kroeger, Nicolaus
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (07): : 374.e1 - 374.e9
  • [38] ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
    Hansen, Doris K.
    Kim, Jongphil
    Thompson, Zachary
    Hussaini, Mohammad
    Nishihori, Taiga
    Ahmad, Anam
    Elmariah, Hany
    Faramand, Rawan
    Mishra, Asmita
    Davila, Marco L.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Sallman, David
    Liu, Hien
    Perez, Lia E.
    Fernandez, Hugo
    Nieder, Michael L.
    Lancet, Jeffrey E.
    Pidala, Joseph A.
    Anasetti, Claudio
    Bejanyan, Nelli
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 256.e1 - 256.e7
  • [39] Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission
    Jiang, Ling
    Cheng, Jiaying
    Sun, Junya
    Zhang, Yujiao
    Wu, Quan
    Huang, Yun
    Long, Zhiquan
    Yan, Ping
    Jiang, Xuejie
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (01) : 250 - 262
  • [40] Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia
    Buccisano, F.
    Maurillo, L.
    Piciocchi, A.
    Del Principe, M. I.
    Picardi, A.
    Cerretti, R.
    Cudillo, L.
    De Angelis, G.
    Sarlo, C.
    Cefalo, M.
    Ditto, C.
    Di Veroli, A.
    Mariotti, B.
    Nasso, D.
    De Bellis, E.
    Del Poeta, G.
    Voso, M. T.
    Sconocchia, G.
    Lo Coco, F.
    Arcese, W.
    Amadori, S.
    Venditti, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (03) : 473 - 475
12345